Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome

Neurol Clin. 2021 Feb;39(1):133-146. doi: 10.1016/j.ncl.2020.09.007. Epub 2020 Nov 7.

Abstract

Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults with NMJ disorders are most often antibody mediated, with MG being the most common, having a prevalence of approximately 1 in 10,000, and with women being affected about twice as often as men. This article focuses on advances in management of autoimmune MG and LEMS.

Keywords: Complement inhibitor; Lambert Eaton myasthenic syndrome; Myasthenia gravis; Thymectomy; Weakness.

Publication types

  • Review

MeSH terms

  • Adult
  • Female
  • Humans
  • Lambert-Eaton Myasthenic Syndrome / diagnosis
  • Lambert-Eaton Myasthenic Syndrome / therapy*
  • Male
  • Myasthenia Gravis / diagnosis
  • Myasthenia Gravis / therapy*